SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

• Published in: Clinical & translational oncology Vol. 24; no. 4; pp. 703 - 711
• Main Authors: Martínez-García, María, Servitja Tormo, Sonia, Vilariño Quintela, Noelia, Arance Fernández, Ana, Berrocal Jaime, Alfonso, Cantos Sánchez de Ibargüen, Blanca, Del Barco Berrón, Sonia, García Campelo, Rosario, Gironés Sarrió, Regina, Manuel Sepúlveda-Sánchez, Juan
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-04-2022
• Subjects: Brain; Brain Neoplasms - secondary; Central Nervous System - pathology; Central Nervous System Neoplasms - secondary; Central Nervous System Neoplasms - therapy; Clinical Guides in Oncology; Humans; Lung Neoplasms - pathology; Medicine; Medicine & Public Health; Melanoma - pathology; Neoplasms, Second Primary; Oncology; Targeted therapies; Brain metastasis; Immunotherapy; Blood–brain barrier; Guidelines
• ISSN: 1699-3055; 1699-048X; 1699-3055
• DOI: 10.1007/s12094-022-02803-0

Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.